Oral premalignant lesions (OPLs), often clinically recognized as leukoplakia or erythroplakia, are considered risk factors for development of oral cancer. Oral premalignant lesions are a clinical manifestation of what can be a diffuse process of field cancerization. In patients with treated head and neck cancers, field cancerization contributes to development of second primary tumors, a significant cause of morbidity and mortality.
1 Systemic chemoprevention has been proposed as a method to address the entire mucosal field at risk to halt or reverse carcinogenesis.
2 However, a standard head neck cancer chemoprevention approach has yet to be developed, despite extensive previous clinical investigations of various retinoids,
3-7 interferon,
8 celecoxib,
9 ONYX-015,
10 and Bowman Birk inhibitor concentrate,
11 among other candidate preventive drugs.